International Medical Research Frontier

Objective The purpose of this study is to clarify the pharmacokinetic characteristics of Compound Ginseng/Astragalus/VitaminE and its correlation with lipid-lowering and immunomodulatory effects, so as to provide basis for rational drug use in clinic. Methods 120 patients with hyperlipidemia and hypoimmunity were randomly divided into single drug group (Compound Ginseng/Astragalus/VitaminE) and combined group (atorvastatin). The pharmacokinetic parameters of ginsenoside Rg1, astragaloside IV and vitamin E were determined by intensive blood sampling method, and their relationships with lipid-lowering (TC, TG) and immune indexes (CD4⁺T cells, NK activity) were analyzed. Results Ginsenoside Rg1 was absorbed quickly (T~max~=2.1 h) and eliminated at a moderate speed (t ~ 1/2 ~ = 4.8 h). Astragaloside iv has a long-term sustained release (T~max~=4.2 h, t ~ 1/2 ~ = 8.5 h); Vitamin e is easy to accumulate (t~1/2~=18.2 h). The lipid-lowering effect of combined group was significant (TC decreased by 28.7% vs single drug group by 18.2%), and the immune index of single drug group increased by 42%. Conclusion The pharmacokinetic characteristics of Compound Ginseng/Astragalus/VitaminE support the regimen of three times a day, and its lipid-lowering and immunomodulatory effects depend on the continuous exposure of components. The risk of vitamin E accumulation needs to pay attention to special people, and the combination of statins can enhance the synergy of lipid lowering.

Compound Ginseng/Astragalus/VitaminE; Pharmacokinetics; Clinical